MyFinsight
Home
Blog
About
Net proceeds from
sale of common stock...
$1,507,738
(1893.89%↑ Y/Y)
Maturities of marketable
investment securities
$6,500,000
(-25.29%↓ Y/Y)
Cash provided by
financing activities
$1,507,738
(1893.89%↑ Y/Y)
Net cash provided by
(used in) investing...
$1,484,511
(-58.97%↓ Y/Y)
Canceled cashflow
$5,015,489
Net decrease in cash
and cash...
-$36,178
(77.66%↑ Y/Y)
Canceled cashflow
$2,992,249
Accrued expenses
$422,317
(279.36%↑ Y/Y)
Prepaid and other
current assets
-$106,051
(48.34%↑ Y/Y)
Stock-based compensation
expense
$58,145
(-57.31%↓ Y/Y)
Depreciation expense
$14,648
(-53.76%↓ Y/Y)
Accrued interest income
-$10,346
(-905.14%↓ Y/Y)
Purchases of marketable
investment securities
$5,015,489
(-1.31%↓ Y/Y)
Cash used in
operating activities
-$3,028,427
(21.45%↑ Y/Y)
Canceled cashflow
$611,507
Net loss
attributable to common...
-$2,622,595
(35.57%↑ Y/Y)
Accounts payable
-$882,203
(-615.01%↓ Y/Y)
License and royalties
receivable
$70,702
Amortization of discounts on
marketable investment...
$64,434
(-30.44%↓ Y/Y)
Back
Back
Cash Flow
Lipocine Inc. (LPCN)
Lipocine Inc. (LPCN)
source: myfinsight.com